Biologics are transforming the treatment of numerous diseases, but many CNS diseases remain largely out of reach due to the challenge of crossing the blood-brain barrier and navigating the brain’s unique immune environment. Aliada is redefining what is possible in CNS drug development by building on a highly versatile and differentiated platform, with demonstrated proof of concept in NHPs. We are expanding this platform across a wide range of modalities, including monoclonal antibodies, enzymes, oligonucleotides, peptides, and other proteins. The delivery technology is customizable to CNS tissue and target localization via novel approaches to binding two distinct transport targets on the blood-brain barrier. In addition to the platform, Aliada is applying its novel technology to specific CNS target antibody binders and progressing these programs through preclinical evaluation.
